

FILE 'USPAT' ENTERED AT 10:55:37 ON 09 JUN  
1999

\*\*\*\*\*  
\*\*\*\*\*  
\* U. S. P A T E N T T E X T F  
I L E \*

\* THE WEEKLY PATENT TEXT AND IMAGE DATA IS  
CURRENT \*

\* THROUGH June 8, 1999.

\*  
\*  
\*  
\*  
\*\*\*\*\*  
\*\*\*\*\*

=> s igf? or (insulin?(3a)(growth factor?))

3040 IGF?  
11831 INSULIN?  
150692 GROWTH  
450761 FACTOR?  
11216 GROWTH FACTOR?  
(GROWTH(W) FACTOR?)  
1873 INSULIN?(3A)(GROWTH FACTOR?)  
L1 3946 IGF? OR (INSULIN?(3A)(GROWTH  
FACTOR?))

=> s l1 and (neur? or nerv? or brain?)

31785 NEUR?  
27767 NERV?  
25990 BRAIN?  
L2 1465 L1 AND (NEUR? OR NERV? OR  
BRAIN?)

=> d 1-20

1. 5,910,574, Jun. 8, 1999, Human trk  
receptors and neurotrophic  
factor inhibitors; Leonard G. Presta, et al.,  
530/388.22; 424/133.1,  
143.1; 530/387.3, 388.1 [IMAGE AVAILABLE]

2. 5,910,480, Jun. 8, 1999, Protein called  
epil/placentin, process for  
the preparation of this protein and  
pharmaceutical composition containing  
such, DNA coding for said Protein; Ahmet  
Koman, et al., 514/12; 435/69.1;  
514/2; 530/303, 350, 399 [IMAGE AVAILABLE]

3. 5,908,934, Jun. 1, 1999, Process for the  
preparation of chiral ketone  
intermediates useful for the preparation of  
flavopiridol and analogs;  
Kyoung Soon Kim, 546/216, 186, 194, 208, 210,  
213, 214, 219, 220, 221,  
222 [IMAGE AVAILABLE]

4. 5,908,782, Jun. 1, 1999, Chemically  
defined medium for human

mesenchymal stem cells; Daniel R. Marshak, et  
al., 435/366; 424/93.7;  
435/371, 372, 383, 384, 388, 389, 404, 405,  
407 [IMAGE AVAILABLE]

5. 5,908,765, Jun. 1, 1999, Method of  
recovering a biological molecule  
from a recombinant microorganism; Peter S.  
Carlson, et al., 435/91.41  
[IMAGE AVAILABLE]

6. 5,908,623, Jun. 1, 1999, Compositions and  
methods for the delivery of  
biologically active molecules using  
genetically altered cells contained  
in biocompatible immunoisulatory capsules;  
Edward E. Baetge, et al.,  
424/93.21, 93.2 [IMAGE AVAILABLE]

7. 5,908,609, Jun. 1, 1999, Screening  
methods for compounds useful in  
the regulation of body weight; Frank Lee, et  
al., 424/9.2; 435/6, 7.21,  
8, 21, 29; 530/399 [IMAGE AVAILABLE]

8. 5,906,828, May 25, 1999, Cell growth  
substrates with tethered cell  
growth effector molecules; Linda G. Cima, et  
al., 424/423, 426, 443, 484,  
486, 488; 435/29, 178, 179, 180, 181, 182,  
370, 372, 398, 399, 400, 402;  
514/12, 21; 530/812, 815, 816 [IMAGE  
AVAILABLE]

9. 5,906,636, May 25, 1999, Heat treatment  
of inflamed tissue; S. Ward  
Casscells, III, et al., 607/96; 606/27 [IMAGE  
AVAILABLE]

10. 5,905,146, May 18, 1999, DNA binding  
protein S1-3; Beata  
Lecka-Czernik, 536/23.5; 435/252.3, 320.1,  
325; 536/24.31 [IMAGE  
AVAILABLE]

11. 5,905,142, May 18, 1999, Protease  
resistant PDGF and methods of use;  
Mark J. Murray, 530/399, 350 [IMAGE  
AVAILABLE]

12. 5,905,068, May 18, 1999, Retroviral  
protease inhibiting compounds;  
Xiaoqi Chen, et al., 514/19; 424/185.1;  
514/885; 544/242; 548/217, 305.1,  
305.4; 549/546 [IMAGE AVAILABLE]

13. 5,905,041, May 18, 1999, Process for  
preparing and cultivating  
hematopoietic progenitor cells; Hartmut Beug,  
et al., 435/372, 355, 375,  
377 [IMAGE AVAILABLE]

14. 5,904,718, May 18, 1999, Delayed drug  
delivery system; Steven R.  
Jefferies, 623/16; 128/898; 606/76; 623/11,  
66 [IMAGE AVAILABLE]

15. 5,902,799, May 11, 1999, Methods of modulating tissue growth and regeneration; Howard C. Herrmann, et al., 514/58, 21; 530/810, 813, 817 [IMAGE AVAILABLE]

16. 5,902,785, May 11, 1999, Cartilage induction by bone morphogenetic proteins; Gary Hattersley, et al., 514/2, 8, 12 [IMAGE AVAILABLE]

17. 5,902,741, May 11, 1999, Three-dimensional cartilage cultures; Anthony F. Purchio, et al., 424/572, 574; 435/1.1; 623/15 [IMAGE AVAILABLE]

18. 5,902,617, May 11, 1999, Enzyme supplemented baby formula; Patrea L. Pabst, 426/61, 34, 35, 62, 63, 801 [IMAGE AVAILABLE]

19. 5,902,598, May 11, 1999, Sustained release drug delivery devices; Jianbing Chen, et al., 424/423, 422, 424, 425, 427, 468; 604/890.1, 891.1, 892.1 [IMAGE AVAILABLE]

20. 5,900,404, May 4, 1999, Chemical modification of proteins to improve biocompatibility and bioactivity; Colin Gegg, et al., 514/12, 2; 530/324, 402, 412 [IMAGE AVAILABLE]

=> s (igf? or (insulin?(3a)(growth factor?)))/clm

511 IGF?/CLM  
1649 INSULIN?/CLM  
22097 GROWTH/CLM  
31256 FACTOR?/CLM  
1702 GROWTH FACTOR?/CLM  
((GROWTH(W)FACTOR?)/CLM)  
270 INSULIN?(3A)(GROWTH FACTOR?)  
L3 705 (IGF? OR (INSULIN?(3A)(GROWTH FACTOR?)))/CLM

=> s ((igf? or (insulin?(3a)(growth factor?))and (nerv? or neur? or brain?)))/clm

511 IGF?/CLM  
1649 INSULIN?/CLM  
22097 GROWTH/CLM  
31256 FACTOR?/CLM  
1702 GROWTH FACTOR?/CLM  
((GROWTH(W)FACTOR?)/CLM)  
270 INSULIN?(3A)(GROWTH FACTOR?)  
2335 NERV?/CLM  
4752 NEUR?/CLM  
1838 BRAIN?/CLM  
L4 97 ((IGF? OR (INSULIN?(3A)(GROWTH FACTOR?))AND (NERV? OR NEUR ? O  
R BRAIN?)))/CLM

=> d 1-20

1. 5,908,623, Jun. 1, 1999, Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisulatory capsules; Edward E. Baetge, et al., 424/93.21, 93.2 [IMAGE AVAILABLE]

2. 5,904,718, May 18, 1999, Delayed drug delivery system; Steven R. Jefferies, 623/16; 128/898; 606/76; 623/11, 66 [IMAGE AVAILABLE]

3. 5,902,799, May 11, 1999, Methods of modulating tissue growth and regeneration; Howard C. Herrmann, et al., 514/58, 21; 530/810, 813, 817 [IMAGE AVAILABLE]

4. 5,888,533, Mar. 30, 1999, Non-polymeric sustained release delivery system; Richard L. Dunn, 424/423, 426 [IMAGE AVAILABLE]

5. 5,874,164, Feb. 23, 1999, Barrier webs having bioactive surfaces; J. Michael Caldwell, 428/306.6; 424/278.1, 443, 499; 428/308.4, 422, 447; 442/76, 79, 82 [IMAGE AVAILABLE]

6. 5,872,241, Feb. 16, 1999, Multiple component RNA catalysts and uses thereof; Anna M. Pyle, et al., 536/24.5; 435/6, 91.31, 375 [IMAGE AVAILABLE]

7. 5,869,337, Feb. 9, 1999, Regulated transcription of targeted genes and other biological events; Gerald R. Crabtree, et al., 435/372.3, 320.1, 325, 366; 536/23.4 [IMAGE AVAILABLE]

8. 5,866,113, Feb. 2, 1999, Medical device with biomolecule-coated surface graft matrix; Marc Hendriks, et al., 424/78.17, 78.18, 486, 487; 427/2.24, 2.25, 2.28, 2.3; 525/78; 530/815, 816 [IMAGE AVAILABLE]

9. 5,861,373, Jan. 19, 1999, IGF-1 to improve the neural condition; Peter Gluckman, et al., 514/3, 12 [IMAGE AVAILABLE]

10. 5,856,245, Jan. 5, 1999, Articles of barrier webs; J. Michael Caldwell, et al., 442/76; 128/849, 888; 424/404; 442/79, 123, 152, 153, 164; 602/48, 50; 604/372, 374, 377 [IMAGE AVAILABLE]

11. 5,854,207, Dec. 29, 1998, Compositions and therapeutic methods using morphogenic proteins and stimulatory factors; John C. Lee, et al., 514/2,

21 [IMAGE AVAILABLE]

12. 5,843,899, Dec. 1, 1998, Use of insulin-like growth factors I and II for inhibition of inflammatory response; Philip F. Halloran, 514/12, 3, 4, 21 [IMAGE AVAILABLE]

13. 5,840,736, Nov. 24, 1998, Methods and compositions for stimulating neurite growth; Robert E. Zelle, et al., 514/332, 12, 341 [IMAGE AVAILABLE]

14. 5,830,462, Nov. 3, 1998, Regulated transcription of targeted genes and other biological events; Gerald R. Crabtree, et al., 424/93.21; 435/375, 456, 463, 465; 514/44 [IMAGE AVAILABLE]

15. 5,821,047, Oct. 13, 1998, Monovalent phage display; Lisa J. Garrard, et al., 435/5, 68.1, 69.1, 69.7, 69.8, 235.1, 239; 436/802; 530/350, 387.1, 387.9; 536/24.1 [IMAGE AVAILABLE]

16. 5,811,434, Sep. 22, 1998, Methods and compositions for stimulating neurite growth; Robert E. Zelle, et al., 514/307, 237.2, 314, 315, 318, 330, 332, 351; 544/129; 546/139, 192, 193, 194, 245, 256, 300 [IMAGE AVAILABLE]

17. 5,808,006, Sep. 15, 1998, Refolding of polypeptides like recombinant insulin-like growth factor IGF-I; Stuart Builder, et al., 530/399; 435/69.4, 252.3, 320.1; 530/303, 350, 418, 419, 420, 422, 423, 424 [IMAGE AVAILABLE]

18. 5,804,550, Sep. 8, 1998, Peptide antagonists at glutamate and NMDA receptors; J. P. Bourguignon, 514/3, 4, 12, 13 [IMAGE AVAILABLE]

19. 5,804,417, Sep. 8, 1998, Recombinant production of proteins using 7B2 protein; Gerardus Julianus Maria Martens, et al., 435/69.1, 252.3, 254.2, 325, 419; 530/333, 350, 351, 381; 536/23.5 [IMAGE AVAILABLE]

20. 5,801,190, Sep. 1, 1998, Fused pyrrolo[2,3-C] carbazole-6-ones; Robert L. Hudkins, et al., 514/410; 548/416, 417 [IMAGE AVAILABLE]

=> d his

(FILE 'USPAT' ENTERED AT 10:55:37 ON 09 JUN 1999)

L1 3946 S IGF? OR  
(INSULIN?(3A) (GROWTH FACTOR?))

L2 1465 S L1 AND (NEUR? OR NERV? OR BRAIN?)

L3 705 S (IGF? OR  
(INSULIN?(3A) (GROWTH FACTOR?)))/CLM

L4 97 S ((IGF? OR  
(INSULIN?(3A) (GROWTH FACTOR?)))AND (NERV? OR  
N  
EUR

=> d 90-97

90. 5,128,320, Jul. 7, 1992, Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering IGF-I; Theodore J. Hahn, et al., 514/12, 21 [IMAGE AVAILABLE]

91. 5,110,604, May 5, 1992, Processes for producing collagen matrixes and methods of using same; George H. Chu, et al., 424/484; 128/DIG.8; 424/85.2, 85.4, 422; 514/801; 530/356, 399; 604/890.1; 623/11 [IMAGE AVAILABLE]

92. 5,093,317, Mar. 3, 1992, Treating disorders by application of insulin-like growth factor; Michael E. Lewis, et al., 514/12; 424/556, 570; 514/3, 4, 21, 885, 903 [IMAGE AVAILABLE]

93. 5,068,224, Nov. 26, 1991, Method of improving regeneration of transfected peripheral nerves using IGF-1; Linda Fryklund, et al., 514/21, 3, 4, 12 [IMAGE AVAILABLE]

94. 5,024,841, Jun. 18, 1991, Collagen wound healing matrices and process for their production; George H. Chu, et al., 424/422; 128/DIG.8; 424/85.2, 85.4, 426, 484; 514/56, 801; 530/356, 399; 604/890.1; 623/11 [IMAGE AVAILABLE]

95. 4,801,575, Jan. 31, 1989, Chimeric peptides for neuropeptide delivery through the blood-brain barrier; William M. Pardridge, 514/4; 424/85.7; 514/2, 3; 530/302, 303, 311, 351; 930/21, 24, 80, 150, 160, 260, DIG.565, DIG.570, DIG.620, DIG.700, DIG.720 [IMAGE AVAILABLE]

96. 4,743,552, May 10, 1988, Method for growth in tissue culture of normal colonic epithelial cells and method for determination of preneoplastic color cells; Eileen A. Friedman, et al., 435/381, 29, 30, 34, 35, 244, 384, 387, 389, 402 [IMAGE AVAILABLE]

97. 4,543,439, Sep. 24, 1985, Production and use of monoclonal antibodies to phosphotyrosine-containing proteins; A. Raymond Frackelton, Jr., et al., 435/70.21, 345, 948; 436/501, 513; 530/388.1, 388.2, 388.22 [IMAGE AVAILABLE]

=> d 80-89

80. 5,288,856, Feb. 22, 1994, Method of isolating acid-stable, biologically active proteins; Pierre Amiguet, 530/419, 322, 344, 372, 395, 412, 417, 418, 420, 422 [IMAGE AVAILABLE]

81. 5,272,135, Dec. 21, 1993, Method for the stabilization of methionine-containing polypeptides; Harun Takruri, 514/12, 21; 530/399 [IMAGE AVAILABLE]

82. 5,264,214, Nov. 23, 1993, Composition for bone repair; Woonza Rhee, et al., 424/422, 423, 426; 523/113, 115; 604/891.1 [IMAGE AVAILABLE]

83. 5,262,322, Nov. 16, 1993, Host transformed with yeast gene and ubiquitin/polypeptide fusions; Chung-Cheng Liu, et al., 435/252.33, 69.7, 195, 224, 252.3, 320.1; 536/23.2, 23.4 [IMAGE AVAILABLE]

84. 5,225,212, Jul. 6, 1993, Microreservoir liposome composition and method; Francis J. Martin, et al., 424/450, 78.31, 426 [IMAGE AVAILABLE]

85. 5,219,576, Jun. 15, 1993, Collagen wound healing matrices and process for their production; George H. Chu, et al., 424/484; 128/DIG.8; 424/85.2, 85.4, 422; 514/21, 801, 887; 623/11 [IMAGE AVAILABLE]

86. 5,210,017, May 11, 1993, Ligand-mediated immunofunctional hormone binding protein assay method; Lena M. S. Carlsson, et al., 435/7.8, 7.21, 7.94, 975; 436/501, 518, 548 [IMAGE AVAILABLE]

87. 5,182,195, Jan. 26, 1993, Method for increasing gene expression using protease deficient yeasts; Kazuo Nakahama, et al., 435/69.1, 69.4, 206, 254.21, 942 [IMAGE AVAILABLE]

88. 5,162,430, Nov. 10, 1992, Collagen-polymer conjugates; Woonza Rhee, et al., 525/54.1; 523/113; 530/356 [IMAGE AVAILABLE]

89. 5,143,661, Sep. 1, 1992, Silicone-hardened pharmaceutical microcapsules; James R. Lawter, et al., 264/4.3, 4.6; 424/460; 427/213.32, 213.36; 514/963 [IMAGE AVAILABLE]

=> d 21-79

21. 5,798,266, Aug. 25, 1998, Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer; Steven C. Quay, et al., 436/64; 435/6, 7.1, 7.2, 7.23, 7.9, 7.91, 7.92, 7.93, 7.94, 7.95, 29, 30, 287.7, 810, 975; 436/161, 162, 177, 178, 501, 514, 523, 807, 808, 810, 813; 604/74, 75, 76 [IMAGE AVAILABLE]

22. 5,795,726, Aug. 18, 1998, Methods for identifying compounds useful in treating type II diabetes; M. Alexandra Glucksmann, 435/7.21, 4, 6, 8; 536/23.5 [IMAGE AVAILABLE]

23. 5,783,566, Jul. 21, 1998, Method for increasing or decreasing transfection efficiency; Kimberly Ann Mislick, 514/44; 424/450; 435/325, 458; 514/1, 2 [IMAGE AVAILABLE]

24. 5,780,484, Jul. 14, 1998, Methods for stimulating neurite growth with piperidine compounds; Robert E. Zelle, et al., 514/316, 12, 237.2, 314, 317, 318 [IMAGE AVAILABLE]

25. 5,780,279, Jul. 14, 1998, Method of selection of proteolytic cleavage sites by directed evolution and phagemid display; David J. Matthews, et al., 435/6, 69.1, 243, 320.1, 325, 472, 488; 530/300, 399 [IMAGE AVAILABLE]

26. 5,776,897, Jul. 7, 1998, Treating disorders by application of insulin-like growth factors and analogs; Michael E. Lewis, et al., 514/12, 21 [IMAGE AVAILABLE]

27. 5,773,245, Jun. 30, 1998, Methods for increasing secretion of overexpressed proteins; Karl Dane Wittrup, et al., 435/69.1, 69.2, 69.3, 69.51, 69.52, 69.6, 69.7 [IMAGE AVAILABLE]

28. 5,766,627, Jun. 16, 1998, Multivesicular liposomes with controlled release of encapsulated biologically active substances; Mantripragada Bhima Sankaram, et al., 424/450; 264/4.1, 4.3, 4.6; 424/1.21, 9.321, 9.51, 417; 436/829 [IMAGE AVAILABLE]

29. 5,762,924, Jun. 9, 1998, Recombinant entomopoxvirus; David James Dall, et al., 424/93.2, 93.6; 435/69.1, 235.1, 320.1; 536/23.72, 24.1 [IMAGE AVAILABLE]
30. 5,762,922, Jun. 9, 1998, Antioxidants and intracellular glutathione raising agents for therapeutic treatments; Mark David Noble, et al., 424/85.4, 85.1; 530/351, 399 [IMAGE AVAILABLE]
31. 5,756,672, May 26, 1998, Refolding of polypeptides; Stuart Builder, et al., 530/350; 435/69.1, 252.3, 320.1; 530/418, 419, 420, 422, 423, 424 [IMAGE AVAILABLE]
32. 5,756,122, May 26, 1998, Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacture and use thereof for transfection of targeted cells; Alain Thierry, et al., 424/450 [IMAGE AVAILABLE]
33. 5,750,376, May 12, 1998, In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny; Samuel Weiss, et al., 435/69.52, 69.1, 325, 368, 377, 384, 392, 395, 455, 456, 458, 461 [IMAGE AVAILABLE]
34. 5,741,776, Apr. 21, 1998, Method of administration of IGF-I; Ross G. Clark, et al., 514/12, 4, 21 [IMAGE AVAILABLE]
35. 5,736,516, Apr. 7, 1998, Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein protein; Jean-Claude Louis, 514/12; 435/69.1, 69.4; 530/391.9, 399 [IMAGE AVAILABLE]
36. 5,736,152, Apr. 7, 1998, Non-polymeric sustained release delivery system; Richard L. Dunn, 424/426; 514/772.3 [IMAGE AVAILABLE]
37. 5,733,761, Mar. 31, 1998, Protein production and protein delivery; Douglas Treco, et al., 435/463, 69.4; 536/23.51, 24.1 [IMAGE AVAILABLE]
38. 5,733,572, Mar. 31, 1998, Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles; Evan C. Unger, et al., 424/450, 1.21, 9.321, 9.4, 489; 436/829 [IMAGE AVAILABLE]
39. 5,723,147, Mar. 3, 1998, Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride; Sinil Kim, et al., 424/450 [IMAGE AVAILABLE]
40. 5,721,139, Feb. 24, 1998, Isolating and culturing schwann cells; Jennie P. Mather, et al., 435/383, 325, 363, 366, 368, 384, 387 [IMAGE AVAILABLE]
41. 5,714,460, Feb. 3, 1998, IFG-1 to improve neural outcome; Peter Gluckman, et al., 514/3 [IMAGE AVAILABLE]
42. 5,713,891, Feb. 3, 1998, Modified solder for delivery of bioactive substances and methods of use thereof; Dix P. Poppas, 606/2, 8, 213, 214 [IMAGE AVAILABLE]
43. 5,708,140, Jan. 13, 1998, Production of proteins using 7B2 protein; Gerardus Julianus Maria Martens, et al., 530/350, 333 [IMAGE AVAILABLE]
44. 5,707,962, Jan. 13, 1998, Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof; Charles C. Chen, et al., 514/12; 128/DIG.8; 424/85.1, 422, 423; 514/21, 801; 530/351, 356, 399, 840; 623/16, 66 [IMAGE AVAILABLE]
45. 5,703,045, Dec. 30, 1997, Treating disorders by application of insulin-like growth factors and analogs; Michael E. Lewis, et al., 514/12, 2; 530/317, 324 [IMAGE AVAILABLE]
46. 5,681,873, Oct. 28, 1997, Biodegradable polymeric composition; Richard L. Norton, et al., 523/115; 424/426, 486; 523/105, 113, 114; 528/354 [IMAGE AVAILABLE]
47. 5,674,703, Oct. 7, 1997, Episomal vector systems and related methods; Savio L. C. Woo, et al., 435/69.1, 69.4, 69.5, 69.6, 70.1, 320.1 [IMAGE AVAILABLE]
48. 5,674,694, Oct. 7, 1997, Clonogenic assay for detecting micro levels of tumor cells in hematopoietic samples; Amelia Ann Ross, 435/7.23, 34, 347, 366, 373; 436/64 [IMAGE AVAILABLE]
49. 5,656,481, Aug. 12, 1997, Compositions and methods for the delivery of biologically active molecules using cells contained in biocompatible capsules; Edward E. Baetge, et al., 435/325; 424/93.1, 93.2, 93.21, 93.3, 93.7; 435/347, 373, 382 [IMAGE AVAILABLE]

50. 5,653,975, Aug. 5, 1997, Compositions and methods for the delivery of biologically active molecules using cells contained in biocompatible capsules; Edward E. Baetge, et al., 424/93.1, 93.2, 93.21, 93.3, 93.7 [IMAGE AVAILABLE]
51. 5,652,214, Jul. 29, 1997, Treating disorders by application of insulin-like growth factors and analogs; Michael E. Lewis, et al., 514/12, 21 [IMAGE AVAILABLE]
52. 5,652,136, Jul. 29, 1997, Substrate assisted catalysis; Paul John Carter, et al., 435/252.3, 221, 222, 320.1; 536/23.4 [IMAGE AVAILABLE]
53. 5,648,335, Jul. 15, 1997, Prevention and treatment of peripheral neuropathy; Michael E. Lewis, et al., 514/12, 2, 21 [IMAGE AVAILABLE]
54. 5,641,750, Jun. 24, 1997, Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product; Jean-Claude Louis, 514/12; 435/69.1, 69.4 [IMAGE AVAILABLE]
55. 5,641,670, Jun. 24, 1997, Protein production and protein delivery; Douglas A. Treco, et al., 435/254.11, 320.1, 326, 366, 367, 371, 372, 372.2, 372.3 [IMAGE AVAILABLE]
56. 5,633,228, May 27, 1997, Prevention and treatment of peripheral neuropathy; Michael E. Lewis, et al., 514/12, 2, 21 [IMAGE AVAILABLE]
57. 5,629,286, May 13, 1997, Homeopathic dilutions of growth factors; Barbara Brewitt, 514/2; 530/303, 351 [IMAGE AVAILABLE]
58. 5,626,617, May 6, 1997, Methods for treating disorders by administering radio frequency signals corresponding to growth factors; Barbara Brewitt, 607/2; 128/898; 601/15; 604/20 [IMAGE AVAILABLE]
59. 5,622,932, Apr. 22, 1997, IGF-1 superagonists; Richard D. DiMarchi, et al., 514/12, 21; 530/324, 399 [IMAGE AVAILABLE]
60. 5,597,485, Jan. 28, 1997, Process for separating proteins; Jorge A. Mazza, et al., 210/635, 198.2, 656; 530/413, 417 [IMAGE AVAILABLE]
61. 5,593,844, Jan. 14, 1997, Ligand-mediated immunofunctional hormone binding protein assay method; Lena M. S. Carlsson, et al., 435/7.1, 7.8, 7.92, 336; 530/388.1, 388.24 [IMAGE AVAILABLE]
62. 5,584,885, Dec. 17, 1996, Nerve regeneration chamber; Brooke R. Seckel, 623/11; 435/1.2, 284.1; 606/152 [IMAGE AVAILABLE]
63. 5,578,324, Nov. 26, 1996, Peptide proteinaceous drug nasal powder composition; Masahiko Dohi, et al., 424/499, 489, 490 [IMAGE AVAILABLE]
64. 5,569,648, Oct. 29, 1996, Prevention and treatment of peripheral neuropathy; Michael E. Lewis, et al., 514/12, 2, 21 [IMAGE AVAILABLE]
65. 5,549,904, Aug. 27, 1996, Biological adhesive composition and method of promoting adhesion between tissue surfaces; Kay Juergensen, et al., 424/423; 514/2, 12, 21, 955; 530/835, 840, 841, 842, 846, 850 [IMAGE AVAILABLE]
66. 5,543,441, Aug. 6, 1996, Implants coated with collagen-polymer conjugates; Woonza Rhee, et al., 523/105; 525/935; 604/891.1 [IMAGE AVAILABLE]
67. 5,510,121, Apr. 23, 1996, Glycosaminoglycan-synthetic polymer conjugates; Woonza M. Rhee, et al., 424/520, 529, 531, 537, 546, 548, 577, 578, 579, 580 [IMAGE AVAILABLE]
68. 5,506,120, Apr. 9, 1996, Method of producing peptides or proteins as fusion proteins; Hiroaki Yamamoto, et al., 435/69.7, 69.1, 69.2, 69.3, 69.4, 69.5, 69.6, 69.8, 252.3, 320.1; 536/23.4 [IMAGE AVAILABLE]
69. 5,455,164, Oct. 3, 1995, Ruminant immortalized mammary epithelial cell lines; Jeffrey D. Turner, 435/6, 69.1, 325, 948 [IMAGE AVAILABLE]
70. 5,451,660, Sep. 19, 1995, Method for purifying polypeptides; Stuart E. Builder, et al., 530/344, 300, 324, 350, 351, 399, 413 [IMAGE AVAILABLE]
71. 5,420,112, May 30, 1995, Prevention and treatment of peripheral neuropathy; Michael E. Lewis, et al., 514/12, 2, 21 [IMAGE AVAILABLE]
72. 5,371,190, Dec. 6, 1994, Substrate assisted catalysis; Paul J. Carter, et al., 530/350; 435/221, 222 [IMAGE AVAILABLE]

73. 5,356,635, Oct. 18, 1994, Carbohydrate glass matrix for the sustained release of a therapeutic agent; Siva N. Raman, et al., 424/484, 423, 425, 426, 468, 488; 514/2, 772.2, 772.3, 777, 783, 785, 786, 787 [IMAGE AVAILABLE]

74. 5,328,955, Jul. 12, 1994, Collagen-polymer conjugates; Woonza Rhee, et al., 525/54.1; 424/422, 423, 426; 523/113, 115 [IMAGE AVAILABLE]

75. 5,311,841, May 17, 1994, Administration of medicaments of poultry; J. Paul Thaxton, 604/506; 119/174; 604/144 [IMAGE AVAILABLE]

76. 5,308,889, May 3, 1994, Dehydrated collagen-polymer strings; Woonza Rhee, et al., 523/113; 424/423; 523/115; 525/54.1; 604/11 [IMAGE AVAILABLE]

77. 5,306,500, Apr. 26, 1994, Method of augmenting tissue with collagen-polymer conjugates; Woonza Rhee, et al., 424/422, 423, 484, 486, 487, 488, 499; 525/54.1 [IMAGE AVAILABLE]

78. 5,304,595, Apr. 19, 1994, Collagen-polymer conjugates; Woonza Rhee, et al., 525/54.1; 523/113; 530/356 [IMAGE AVAILABLE]

79. 5,292,802, Mar. 8, 1994, Collagen-polymer tubes for use in vascular surgery; Woonza Rhee, et al., 525/54.1; 424/422, 423; 523/113 [IMAGE AVAILABLE]

=> e ishii, d/in

E#	FILE	FREQUENCY	TERM
--	----	-----	----
E1	USPAT	2	ISHII, CHIHO/IN
E2	USPAT	1	ISHII, CHISEKI/IN
E3	USPAT	0 -->	ISHII, D/IN
E4	USPAT	2	ISHII, DAIDO/IN
E5	USPAT	2	ISHII, DAIROKU/IN
E6	USPAT	17	ISHII, DAISUKE/IN
E7	USPAT	14	ISHII, EIICHI/IN
E8	USPAT	3	ISHII, EIJI/IN
E9	USPAT	1	ISHII, ETSUKO/IN
E10	USPAT	1	ISHII, ETUMI/IN
E11	USPAT	13	ISHII, FUMIAKI/IN

E12 USPAT 2 ISHII, FUMIKATSU/IN

=> e ishii, douglas/in

E#	FILE	FREQUENCY	TERM
--	----	-----	----
E1	USPAT	2	ISHII, DAIROKU/IN
E2	USPAT	17	ISHII, DAISUKE/IN
E3	USPAT	0 -->	ISHII, DOUGLAS/IN
E4	USPAT	14	ISHII, EIICHI/IN
E5	USPAT	3	ISHII, EIJI/IN
E6	USPAT	1	ISHII, ETSUKO/IN
E7	USPAT	1	ISHII, ETUMI/IN
E8	USPAT	13	ISHII, FUMIAKI/IN
E9	USPAT	2	ISHII, FUMIKATSU/IN
E10	USPAT	21	ISHII, FUMIO/IN
E11	USPAT	1	ISHII, FUMITO/IN
E12	USPAT	1	ISHII, FUMIYOSHI/IN

=> s 5817623/pn

L5 0 5817623/PN

\*\*\*\*\*  
 \* WELCOME TO THE \*  
 \* U.S. PATENT TEXT FILE \*  
 \*\*\*\*\*

=> s (igf## or (insulin?(3a)growth factor?))  
 2262 IGF##  
 8999 INSULIN?  
 129940 GROWTH  
 400971 FACTOR?  
 7769 GROWTH FACTOR?  
 (GROWTH(W)FACTOR?)  
 1191 INSULIN?(3A)GROWTH FACTOR?  
 L1 2860 (IGF## OR (INSULIN?(3A)GROWTH FACTOR?))

=> s l1 and (brain or cns or (central (3a) (nerv? or neuron?)))  
 19772 BRAIN  
 3895 CNS  
 558355 CENTRAL  
 22988 NERV?  
 5630 NEURON?  
 10312 CENTRAL (3A) (NERV? OR NEURON?)  
 L2 476 L1 AND (BRAIN OR CNS OR (CENTRAL (3A)  
 (NERV? OR NEURON?)))

=> d 1-20

1. 5,708,157, Jan. 13, 1998, Secreted proteins and polynucleotides encoding them; Kenneth Jacobs, et al., 536/23.5; 424/559; 435/69.1, 252.3, 254.11, 320.1, 325; 530/300, 350, 850 :IMAGE AVAILABLE:

2. 5,708,142, Jan. 13, 1998, Tumor necrosis factor receptor-associated factors; David V. Goeddel, et al., 530/350; 435/69.1, 252.3, 320.1; 536/23.5 :IMAGE AVAILABLE:

3. 5,708,140, Jan. 13, 1998, Production of proteins using 7B2 protein; Gerardus Julianus Maria Martens, et al., 530/350, 333

4. 5,707,969, Jan. 13, 1998, Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor; Elizabeth G. Nabel, et al., 514/44; 435/6, 69.1, 172.3, 320.1; 935/34, 54, 55, 62, 65, 71 :IMAGE AVAILABLE:

5. 5,707,829, Jan. 13, 1998, DNA sequences and secreted proteins encoded thereby; Kenneth Jacobs, et al., 435/69.1, 252.3, 320.1, 325; 536/23.5 :IMAGE AVAILABLE:

6. 5,707,805, Jan. 13, 1998, Assay for detecting keratinocyte growth factor (KGF) and its activity; Jeffrey S. Rubin, et al., 435/6, 7.1, 7.21 :IMAGE AVAILABLE:

7. 5,707,648, Jan. 13, 1998, Transparent liquid for encapsulated drug delivery; Seang H. Yiv, 424/450; 264/4.1; 428/402.21 :IMAGE AVAILABLE:

8. 5,707,647, Jan. 13, 1998, Adjunctive polymer system for use with medical device; Richard L. Dunn, et al., 424/443; 128/898; 424/78.06, 426, 447; 523/111, 113; 528/905; 602/52, 904 :IMAGE AVAILABLE:

9. 5,707,632, Jan. 13, 1998, Receptors for fibroblast growth factors;

Lewis T. Williams, et al., 424/198.1; 435/7.1, 70.21; 436/548; 530/350, 387.9, 388.22, 389.1, 389.6

10. 5,705,511, Jan. 6, 1998, Fused pyrrolocarbazoles; Robert L. Hudkins, et al., 514/338, 410; 546/256, 276.7; 548/417 :IMAGE AVAILABLE:

11. 5,705,364, Jan. 6, 1998, Mammalian cell culture process; Tina Etcheverry, et al., 435/70.3, 375, 383, 395 :IMAGE AVAILABLE:

12. 5,703,213, Dec. 30, 1997, Monoclonal antibodies which recognize an adenocarcinoma cell antigen; Jack R. Wands, et al., 530/388.85; 435/70.21, 172.2; 530/387.7, 388.8 :IMAGE AVAILABLE:

13. 5,703,048, Dec. 30, 1997, Protection against liver damage by HGF; Filip Roos, et al., 514/12; 435/360; 514/2, 838, 893, 894; 530/350, 399; 935/13 :IMAGE AVAILABLE:

14. 5,703,045, Dec. 30, 1997, Treating disorders by application of \*\*insulin\*\*-like \*\*growth\*\* \*\*factors\*\* and analogs; Michael E. Lewis, et al., 514/12, 2; 530/317, 324 :IMAGE AVAILABLE:

15. 5,702,906, Dec. 30, 1997, Antibodies to neurotrophic factor-4 (NT-4); Arnon Rosenthal, 435/7.1, 236, 336; 530/387.1, 387.9, 388.24, 413 :IMAGE AVAILABLE:

16. 5,702,716, Dec. 30, 1997, Polymeric compositions useful as controlled release implants; Richard L. Dunn, et al., 424/422, 423, 424, 426, 427, 430, 434, 437; 523/105, 113 :IMAGE AVAILABLE:

17. 5,702,700, Dec. 30, 1997, Sertoli cells as neurorecovery inducing cells for Parkinson's disease; Paul R. Sanberg, et al., 424/93.1, 93.7, 558, 562 :IMAGE AVAILABLE:

18. 5,700,924, Dec. 23, 1997, Serpin derived from human hypothalamus; Scott Michael Braxton, et al., 536/23.1; 435/69.1, 91.4, 320.1 :IMAGE AVAILABLE:

19. 5,700,911, Dec. 23, 1997, Bone morphogenetic protein -11 (BMP-11) compositions; John M. Wozney, et al., 530/350; 435/69.4; 530/399; 930/120 :IMAGE AVAILABLE:

20. 5,700,822, Dec. 23, 1997, Treatment of platelet derived growth factor related disorders such as cancers; Klaus Peter Hirth, et al., 514/380, 379 :IMAGE AVAILABLE:

=> d 14 date

L2: 14 of 476

TITLE: Treating disorders by application of \*\*insulin\*\*-like \*\*growth\*\* \*\*factors\*\* and analogs  
 US PAT NO: 5,703,045 DATE ISSUED: Dec. 30, 1997

:IMAGE AVAILABLE:

APPL-NO: 08/462,018 DATE FILED: Jun. 5, 1995  
 REL-US-DATA: Division of Ser. No. 958,903, Oct. 7, 1992, which is a

continuation-in-part of Ser. No. 869,913, Apr. 15, 1992,

abandoned, which is a continuation-in-part of Ser. No. 534,139, Jun. 5, 1990, abandoned, which is a continuation-in-part of Ser. No. 361,595, Jun. 5, 1989, Pat. No. 5,093,317.

=> d 14 clms

US PAT NO: 5,703,045 :IMAGE AVAILABLE: L2: 14 of 476

CLAIMS:

CLMS(1)

We claim:

1. A method of enhancing the survival of non-mitotic neuronal cells of the **\*\*brain\*\*** or spinal cord of a mammal, said cells being at risk of dying due to the effects of a neurological disease, head trauma or spinal cord injury on said neuronal cells, said method comprising administering to said mammal an effective amount of **\*\*insulin\*\***-like **\*\*growth\*\*** **\*\*factor\*\***-II.

CLMS(2)

2. The method of claim 1, wherein said neuronal cells are cholinergic cells.

=> d 21-40

21. 5,700,479, Dec. 23, 1997, Surgical element and method for selective tissue regeneration; Dan Lundgren, 424/435, 422, 423, 426; 623/11 :IMAGE AVAILABLE:

22. 5,700,447, Dec. 23, 1997, Methods and materials for the diagnosis and treatment of conditions such as stroke; Richard J. Bucala, et al., 424/9.1; 436/60, 71 :IMAGE AVAILABLE:

23. 5,698,531, Dec. 16, 1997, Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor; Elizabeth G. Nabel, et al., 514/44; 435/6, 69.1, 172.3, 320.1; 935/34, 54, 55, 62, 65, 71 :IMAGE AVAILABLE:

24. 5,697,901, Dec. 16, 1997, Gene delivery by microneedle injection; Elof Eriksson, 604/46; 435/172.1 :IMAGE AVAILABLE:

25. 5,695,958, Dec. 9, 1997, Aqueous multiple-phase isolation of polypeptide; Stuart Builder, et al., 435/69.1, 70.1, 803; 530/399, 402, 422 :IMAGE AVAILABLE:

26. 5,695,954, Dec. 9, 1997, DNA encoding two fish neuropeptides; Nancy Gail McKeown Sherwood, et al., 435/69.1, 69.2, 69.4, 252.3, 320.1, 325, 365.1; 536/23.1, 23.51; 935/11 :IMAGE AVAILABLE:

27. 5,695,777, Dec. 9, 1997, Absorptive wound dressing for wound healing promotion; Maura G. Donovan, et al., 424/443, 445, 447, 448, 449 :IMAGE AVAILABLE:

28. 5,695,761, Dec. 9, 1997, Suppression of nitric oxide production by osteopontin; David T. Denhardt, et al., 424/184.1, 85.5, 278.1; 514/2, 12; 530/300, 326, 330, 351 :IMAGE AVAILABLE:

29. 5,693,778, Dec. 2, 1997, Arg a human gene related to but distinct from abl proto-oncogene; Gary D. Kruh, et al., 536/23.5; 435/6; 536/23.2, 24.31 :IMAGE AVAILABLE:

30. 5,693,608, Dec. 2, 1997, Method of administering a biologically active substance; Erik Bechgaard, et al., 514/2, 4; 530/300 :IMAGE AVAILABLE:

31. 5,693,522, Dec. 2, 1997, Anti-cancer immunotherapeutics; Sunil Chada, et al., 435/172.3, 320.1; 536/23.1 :IMAGE AVAILABLE:

32. 5,693,010, Dec. 2, 1997, Reduction of skin irritation during electrotransport delivery; Philip W. Ledger, et al., 604/20 :IMAGE AVAILABLE:

33. 5,691,377, Nov. 25, 1997, Use of N-methyl-aspartic acid for enhancing growth and altering body composition; Mark Joseph Estienne, et al., 514/557; 426/656, 805, 807; 514/2, 12; 530/350 :IMAGE AVAILABLE:

34. 5,691,203, Nov. 25, 1997, Method for serum-free culture of human vascular endothelial cells; Susumu Katsuen, et al., 435/402, 177, 180, 366, 395, 396, 404, 407 :IMAGE AVAILABLE:

35. 5,690,954, Nov. 25, 1997, Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material; Lisbeth Illum, 424/434, 489, 499, 500, 501, 502 :IMAGE AVAILABLE:

36. 5,690,926, Nov. 25, 1997, Pluripotent embryonic cells and methods of making same; Brigid L. M. Hogan, 424/93.1, 9.1, 93.21; 435/172.3, 325, 352, 353, 366 :IMAGE AVAILABLE:

37. 5,688,776, Nov. 18, 1997, Crosslinked polysaccharides, process for their preparation and their use; Kurt Heinz Bauer, et al., 514/54, 59; 536/2, 104, 106, 112, 114, 123.1, 123.12 :IMAGE AVAILABLE:

38. 5,688,773, Nov. 18, 1997, Method of selectively destroying neoplastic cells; E. Antonio Chioocca, et al., 514/44; 424/93.1, 93.21; 435/172.3, 320.1 :IMAGE AVAILABLE:

39. 5,688,504, Nov. 18, 1997, Anti-receptor and growth blocking antibodies to the vitamin B.sub.12 /transcobalamin II receptor and binding sites; Alton Charles Morgan, Jr., 424/141.1, 142.1, 143.1, 152.1, 155.1, 156.1 :IMAGE AVAILABLE:

40. 5,688,488, Nov. 18, 1997, Composition and method for tumor imaging; Philip Stewart Low, et al., 424/1.69, 1.41, 450; 435/172.3, 243; 514/2, 44 :IMAGE AVAILABLE:

=> d 41-60

41. 5,686,595, Nov. 11, 1997, Bcl-2-associated proteins; John C. Reed, et al., 536/23.5; 435/172.3; 536/23.1, 24.5 :IMAGE AVAILABLE:
42. 5,686,410, Nov. 11, 1997, Polypeptide derivatives; Rainer Albert, et al., 514/12, 2; 530/324 :IMAGE AVAILABLE:
43. 5,686,116, Nov. 11, 1997, Methods of enhancing repair, healing and augmentation of bone implants; Richard Bockman, et al., 424/650; 514/8, 492 :IMAGE AVAILABLE:
44. 5,683,906, Nov. 4, 1997, Preparation of immortalized cells; Emma E. Moore, 435/325, 172.1, 172.3, 354; 800/2 :IMAGE AVAILABLE:
45. 5,681,873, Oct. 28, 1997, Biodegradable polymeric composition; Richard L. Norton, et al., 523/115; 424/426, 486; 523/105, 113, 114; 528/354 :IMAGE AVAILABLE:
46. 5,681,814, Oct. 28, 1997, Formulated \*\*IGF\*\*-I Composition; Ross G. Clark, et al., 514/12, 2, 21 :IMAGE AVAILABLE:
47. 5,681,568, Oct. 28, 1997, Device for delivery of substances and methods of use thereof; Stanley M. Goldin, et al., 424/184.1; 264/41, 216; 424/422, 423, 424, 443, 449, 468, 472, DIG.7; 514/2, 12, 14; 530/399 :IMAGE AVAILABLE:
48. 5,681,561, Oct. 28, 1997, Compositions and methods for improving autologous fat grafting; Bernard Hirshowitz, et al., 424/93.7, 574; 514/2, 21 :IMAGE AVAILABLE:
49. 5,679,545, Oct. 21, 1997, Gene encoding cardiac hypertrophy factor; Joffre Baker, et al., 435/69.1, 252.3, 320.1, 325; 536/23.5 :IMAGE AVAILABLE:
50. 5,679,511, Oct. 21, 1997, CDNA clones for a regulatory protein in the melanin-production pathway; Byoung Se Kwon, 435/6, 320.1; 530/350; 536/23.2, 23.5 :IMAGE AVAILABLE:
51. 5,677,421, Oct. 14, 1997, Target proteins for eukaryotic tyrosine kinases; Joseph Schlessinger, et al., 530/350; 435/69.1; 536/23.5 :IMAGE AVAILABLE:
52. 5,677,279, Oct. 14, 1997, Methods and compositions for treating pain with amylin or agonists thereof; Andrew A. Young, 514/12 :IMAGE AVAILABLE:
53. 5,676,943, Oct. 14, 1997, Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisulatory capsules; Edward E. Baetge, et al., 424/93.21, 93.3; 435/172.3 :IMAGE AVAILABLE:
54. 5,674,844, Oct. 7, 1997, Treatment to prevent loss of and/or

increase bone mass in metabolic bone diseases; Thangavel Kuberasampath, et al., 514/12, 21 :IMAGE AVAILABLE:

55. 5,674,703, Oct. 7, 1997, Episomal vector systems and related methods; Savio L. C. Woo, et al., 435/69.1, 69.4, 69.5, 69.6, 70.1, 320.1; 935/60 :IMAGE AVAILABLE:
56. 5,674,694, Oct. 7, 1997, Clonogenic assay for detecting micro levels of tumor cells in hematopoietic samples; Amelia Ann Ross, 435/7.23, 34, 347, 366, 373; 436/64 :IMAGE AVAILABLE:
57. 5,672,686, Sep. 30, 1997, Bcl-Y - specific antibodies; Thomas D. Chittenden, 530/387.9, 388.2, 389.1, 391.3 :IMAGE AVAILABLE:
58. 5,672,683, Sep. 30, 1997, Transferrin neuropharmaceutical agent fusion protein; Phillip M. Friden, et al., 530/350; 435/69.7; 530/399, 402; 536/23.4 :IMAGE AVAILABLE:
59. 5,672,584, Sep. 30, 1997, Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability; Ronald T. Borchardt, et al., 514/11; 530/317 :IMAGE AVAILABLE:
60. 5,670,481, Sep. 23, 1997, Dorsal tissue affecting factor (noggin) and compositions comprising same; Richard M. Harland, et al., 514/12; 435/69.1; 514/13, 14, 21; 530/326, 327, 399 :IMAGE AVAILABLE:

=> d 46 date

L2: 46 of 476

TITLE: Formulated \*\*IGF\*\*-I Composition  
US PAT NO: 5,681,814 DATE ISSUED: Oct. 28, 1997  
:IMAGE AVAILABLE:  
APPL-NO: 08/071,819 DATE FILED: Jun. 4, 1993  
REL-US-DATA: Continuation-in-part of Ser. No. 806,748, Dec. 13, 1991,  
abandoned, which is a division of Ser. No. 535,005, Jun. 7, 1990, Pat. No. 5,126,324.

=> d 46 ab

US PAT NO: 5,681,814 :IMAGE AVAILABLE: L2: 46 of 476

ABSTRACT:  
A formulation for \*\*IGF\*\*-I is disclosed that is useful in treating hyperglycemic disorders and, in combination with growth hormone, in enhancing growth of a mammal. Also disclosed is a process for preparing a formulation of growth hormone and \*\*IGF\*\*-I from the \*\*IGF\*\*-I formulation. The \*\*IGF\*\*-I formulation comprises about 2-20 mg/ml of \*\*IGF\*\*-I, about 2-50 mg/ml of an osmolyte, about 1-15 mg/ml of a stabilizer, and a buffered solution at about pH 5-5.5, optionally with a surfactant.

=> d 46 clms

US PAT NO: 5,681,814 :IMAGE AVAILABLE: L2: 46 of 476

# CLAIMS:

## CLMS(1)

What is claimed is:

1. An **IGF**-I-containing composition for subcutaneous administration comprising about 8-12 mg/ml of **IGF**-I, about 5-6 mg/ml of sodium chloride, a stabilizer consisting of about 8-10 mg/ml of benzyl alcohol or about 2-3 mg/ml of phenol, or both about 8-10 mg/ml of benzyl alcohol and about 2-3 mg/ml of phenol, and an about 50 mM sodium acetate buffered solution at a pH of about 5.4.

## CLMS(2)

2. The composition of claim 1 additionally comprising about 1-5 mg/ml of a surfactant.

## CLMS(3)

3. The composition of claim 2 wherein the surfactant is polysorbate or poloxamer in an amount of about 1-3 mg/ml.

## CLMS(4)

4. The composition of claim 3 wherein the surfactant is polysorbate.

## CLMS(5)

5. A method for treating diabetes comprising administering subcutaneously to a mammal having diabetes an amount of the composition of claim 1 effective to treat diabetes.

## CLMS(6)

6. A method for treating diabetes comprising administering subcutaneously to a mammal having diabetes an amount of the composition of claim 2 effective to treat diabetes.

## CLMS(7)

7. A method for treating diabetes comprising administering subcutaneously to a mammal having diabetes an amount of the composition of claim 3 effective to treat diabetes.

## CLMS(8)

8. A method for treating diabetes comprising administering subcutaneously to a mammal having diabetes an amount of the composition of claim 4 effective to treat diabetes.

=> s 5681814/pn  
L3 1 5681814/PN

=> d

1. **5,681,814**, Oct. 28, 1997, Formulated IGF-I Composition; Ross G. Clark, et al., 514/12, 2, 21 :IMAGE AVAILABLE:

=> s l3 and cns  
3895 CNS  
L4 0 L3 AND CNS

=> s l3 brain?  
MISSING OPERATOR 'L3 BRAIN?'

=> s l3 and brain?  
20514 BRAIN?  
L5 1 L3 AND BRAIN?

=> d kwic  
US PAT NO: **5,681,814** :IMAGE AVAILABLE: L5: 1  
of 1

DRAWING DESC:

DRWD(31)

The . . . at the N-terminus. The most preferred variant has the first three amino acids from the N-terminus deleted (variously designated as **brain** IGF, IGF-I, des(1-3)-IGF-I, or des-IGF-I).

DETDESC:

DETD(6)

Alternatively, . . . 1987 and expected to have a specific activity of >about 14,000 U/mg by radioreceptor assay using placenta membranes, or available as **brain** IGF from KabiGen AB, Stockholm, Sweden, >14,000 U/mg by radioreceptor assay using placenta membranes). It was then formulated at 2. . .

DETDESC:

DETD(98)

Sixteen . . . given as needed to maintain anesthesia throughout the study. The right jugular vein was cannulated using Microrenathane.TM. 0.033 OD.times.0.014 ID (**Braintree** Scientific, **Braintree**, Ma.) inserted 23 mm into the jugular. The free end of the cannula was attached to an automated blood sampling. . .

=> s l3 and neuron?  
5630 NEURON?  
L6 0 L3 AND NEURON?

=> s l3 and nerv?  
22988 NERV?  
L7 0 L3 AND NERV?

=> s l3 and spin?  
156860 SPIN?  
L8 1 L3 AND SPIN?

=> d kwic  
US PAT NO: **5,681,814** :IMAGE AVAILABLE: L8: 1  
of 1

SUMMARY:

BSUM(5)

Insulin-like growth factor I (IGF-I) is a polypeptide naturally

occurring in human body fluids, for example, blood and human cerebral  
\*\*spinal\*\* fluid. Most tissues and especially the liver produce IGF-I  
together with specific IGF-binding proteins. These molecules are  
under  
the control. . .